Business Insider

InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer

SHANGHAI, Dec. 28, 2018 /PRNewswire/ -- InventisBio (Shanghai) (hereinafter referred to as "InventisBio") announced today that it has signed a "Collaboration Agreement" with Betta Pharma (hereinafter ...

Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine

On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was ...
BioWorld

Any Betta? FDA adds Ensacove to ALK lung cancer weaponry

A Chinese player entered the U.S. non-small-cell lung cancer (NSCLC) arena as the U.S. FDA cleared Xcovery Holdings Inc.’s Ensacove (ensartinib) as a first-line therapy for adults with anaplastic ...
The New England Journal of Medicine

Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non–small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK ...